Symbols

AIM

AIM ImmunoTech·AMEX

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

Negative Gross Margin

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AIM

Aim Immunotech Inc.

An immuno-pharmaceutical company focused on developing therapies for immune disorders,viruses and cancer diseases

Industry

Biological Technology

Established Date

Listing Date

06/17/2025

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.aimimmuno.com

Security Type

Common stock

Office address

2117 SW Highway 484, Ocala FL

Business

Introduction

AIM ImmunoTech Inc., a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania, is engaged in the clinical development of new drug therapies based on natural immune system enhancement technologies for the treatment of viral and immune-based chronic diseases. The company was founded in the 1970s and is dedicated to doing research for the National Institutes of Health. Since then, the company has established a strong basic laboratory, preclinical and clinical data related to natural interferons and nucleic acids for improving the body's natural antiviral defense system, and the development of certain adjuvant therapy products for chronic diseases. The company has three domestic subsidiaries-BioPro Corp, BioAegean Corp, and Core BioTech Corp, all of which are registered in Delaware and are dormant. The company's foreign subsidiary is emispherx Biopharma Europe N.V./S.A, which was established in Belgium in 1998 and has the smallest business scope. After the consolidation of the company, all balances and transactions between major subsidiaries have been eliminated.

Company Financials

EPS

AIM has released its 2025 Q3 earnings. EPS was reported at -1.57, versus the expected -0.98, missing expectations. The chart below visualizes how AIM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AIM has released its 2025 Q3 earnings report, with revenue of 26.00K, reflecting a YoY change of -25.71%, and net profit of -3.28M, showing a YoY change of 11.24%. The Sankey diagram below clearly presents AIM's revenue sources and cost distribution.